Brain penetration of the OAB drug trospium chloride is not increased in aged mice

World Journal of Urology

Volumn 31, Issue 1, 2013, Pages 219-224

  Kranz, Jasmin ^a   Petzinger, Ernst ^a   Geyer, Joachim ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Ageing; Blood brain barrier; P glycoprotein; Transport; Trospium chloride

Indexed keywords

EID: 84873142495     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0803-z     Document Type: Article

References (32)

1. Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100(5): 987-1006.
2. Wagg A, Verdejo C, Molander U (2010) Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract 64(9): 1279-1286.
3. Wiedemann A, Schwantes PA (2007) Antimuscarinic drugs for the treatment of overactive bladder: are they really all the same?-A comparative review of data pertaining to pharmacological and physiological aspects. Eur J Ger 9: 29-42.
4. Geyer J, Gavrilova O, Schwantes U (2010) Differences in the brain penetration of the anticholinergic drugs trospium chloride and oxybutynin. UroToday Int J 3(1). doi: 10. 3834/uij. 1944-5784. 2010. 02. 12.
5. Callegari E, Malhotra B, Bungay PJ et al (2011) A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 72(2): 235-246.
6. Staskin D, Kay G, Tannenbaum C et al (2010) Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64(9): 1294-1300.
7. Geyer J, Gavrilova O, Petzinger E (2009) The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 37(7): 371-374.
8. Kay GG, Ebinger U (2008) Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 62(11): 792-800.
9. Flurkey K, Currer JM, Harrison DE (2007) The mouse in aging research. In: Fox JG, Barthold S, Davisson M, Newcomer CE, Quimby FW, Smith A (eds) the mouse in biomedical research, 2nd edn. Elsevier, Massachusetts, pp 637-672.
10. Klausner AP, Steers WD (2007) Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects. Curr Urol Rep 8(6): 441-447.
11. Staskin DR (2005) Overactive bladder in the elderly. A guide to pharmacological management. Drugs Aging 22(12): 1013-1028.
12. Holt S, Schmiedl S, Thürmann PA (2010) Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Ärztebl Int 107(31-32): 543-551.
13. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37(1): 13-25.
14. Ueno M, Nakagawa T, Wu B et al (2010) Transporters in the brain endothelial barrier. Curr Med Chem 17(12): 1125-1138.
15. Crone C (1971) The blood-brain barrier-facts and questions. In: Siesjö BK, Sorensen SC (eds) Ion Homeostasis of the Brain. Munksgaard, Copenhagen, pp 52-62.
16. Tamai I, Tsuji A (2000) Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 89(11): 1371-1388.
17. Clark DE (2003) In silico prediction of blood-brain barrier permeation. Drug Discov Today 8(20): 927-933.
18. Shah GN, Mooradian AD (1997) Age-related changes in the blood-brain barrier. Exp Gerontol 32(4-5): 501-519.
19. Wadhwani KC, Koistinaho J, Balbo A, Rapoport SI (1991) Blood-nerve and blood-brain barrier permeabilities and nerve vascular space in Fischer-344 rats of different ages. Mech Ageing Dev 58(2-3): 177-190.
20. Rudick RA, Buell SJ (1983) Integrity of blood-brain barrier to peroxidase in senescent mice. Neurobiol Aging 4(4): 283-287.
21. Farrall AJ, Wardlaw JM (2009) Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 30(3): 337-352.
22. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D (2003) Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2(8): 506-511.
23. Chen RL, Chen CP, Preston JE (2010) Elevation of CSF albumin in old sheep: relations to CSF turnover and albumin extraction at blood-CSF barrier. J Neurochem 113(5): 1230-1239.
24. Reiber H (2003) Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 21(3-4): 79-96.
25. Chen RL (2009) Is it appropriate to use albumin CSF/plasma ratio to assess blood brain barrier permeability? Neurobiol Aging. doi: 10. 1016/j. neurobiolaging. 2008. 08. 024.
26. Bartels AL, Kortekaas R, Bart J et al (2009) Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging 30(11): 1818-1824.
27. Bauer M, Karch R, Neumann F et al (2009) Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur J Clin Pharmacol 65(9): 941-946.
28. Vogelgesang S, Cascorbi I, Schroeder E et al (2002) Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12(7): 535-541.
29. Warrington JS, Greenblatt DJ, von Moltke LL (2004) The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 309(2): 730-736.
30. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1(3): 223-236.
31. Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA (2010) The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc 58(9): 1749-1757.
32. Rapposelli S, Digiacomo M, Balsamo A (2009) P-gp transporter and its role in neurodegenerative diseases. Curr Top Med Chem 9(2): 209-217.